August 12, 2022
AbbVie said on August 10 that it has filed an application in Japan seeking approval for its JAK inhibitor Rinvoq (upadacitinib) for an addition indication of Crohn’s disease. The submission is for the drug’s use as induction and maintenance therapy...read more